Immunic (NASDAQ:IMUX) Cut to Sell at StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

Several other brokerages also recently weighed in on IMUX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, February 21st. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $12.67.

Immunic Trading Up 0.9 %

IMUX opened at $1.15 on Thursday. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11. The company has a market cap of $103.59 million, a price-to-earnings ratio of -0.93 and a beta of 1.89. The company’s 50 day moving average is $1.06 and its 200 day moving average is $1.22.

Institutional Investors Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the stock. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after purchasing an additional 96,894 shares during the last quarter. Millennium Management LLC raised its holdings in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after buying an additional 479,846 shares during the period. Focus Partners Wealth lifted its position in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the last quarter. Finally, 683 Capital Management LLC boosted its stake in shares of Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares during the period. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.